Reuters logo
BRIEF-Kedrion Biopharma, Kamada- FDA accepts rabies immunoglobulin review
November 7, 2016 / 12:13 PM / a year ago

BRIEF-Kedrion Biopharma, Kamada- FDA accepts rabies immunoglobulin review

Nov 7 (Reuters) - Kamada Ltd

* Kamada ltd- pdufa goal date of august 29, 2017

* Kedrion biopharma and kamada announce fda acceptance of bla submission for human rabies immunoglobulin as a post-exposure treatment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below